Login / Signup

Editorial Comment from Dr Miyake to Real-world outcomes of avelumab plus axitinib as first-line therapy in patients with advanced renal cell carcinoma in Japan: A multicenter, retrospective, observational study (J-DART).

Makito Miyake
Published in: International journal of urology : official journal of the Japanese Urological Association (2024)
Keyphrases
  • editorial comment
  • renal cell carcinoma
  • cross sectional
  • metastatic renal cell carcinoma
  • double blind
  • metabolic syndrome
  • cell therapy
  • glycemic control